Sagent will begin marketing and shipping Cefazolin immediately. Cefazolin for injection, USP, is the generic equivalent of GlaxoSmithKline’s Ancef, an antibiotic used to treat bacterial infections.
Cefazolin for injection, USP, is indicated for serious infections such as those of the respiratory, biliary and urinary tracts, skin and skin structure infections, bone and joint infections, and other infections caused by various strains of streptococci.
Jeffrey Yordon, CEO, founder, and chairman of the board of Sagent, said: “This product provides our customers another sourcing option for this important antibiotic and, as with all Sagent products, offers enhanced labeling intended to optimize product safety and increase efficiency in the hospital.”